Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment

BACKGROUND: The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. CASE PRESENTATION: We describe an autoimmune polymyositis following a partial response to combination tremelimumab and durvalumab for the...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Sooraj, Antonia, Scott J., Rose, Trevor A., Seifert, Robert P., Centeno, Barbara A., Wagner, Aaron S., Creelan, Ben C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514517/
https://www.ncbi.nlm.nih.gov/pubmed/28716137
http://dx.doi.org/10.1186/s40425-017-0258-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514517/
https://www.ncbi.nlm.nih.gov/pubmed/28716137
http://dx.doi.org/10.1186/s40425-017-0258-x

Ejemplares similares